Helen Rizos

Helen Rizos

UNVERIFIED PROFILE

Are you Helen Rizos?   Register this Author

Register author
Helen Rizos

Helen Rizos

Publications by authors named "Helen Rizos"

Are you Helen Rizos?   Register this Author

87Publications

1874Reads

46Profile Views

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma.

Cancers (Basel) 2019 Nov 29;11(12). Epub 2019 Nov 29.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11121905DOI Listing
November 2019

Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.

Pigment Cell Melanoma Res 2019 Sep 13. Epub 2019 Sep 13.

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12824DOI Listing
September 2019

Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery.

Biomacromolecules 2019 May 24;20(5):2148-2158. Epub 2019 Apr 24.

Department of Biomedical Sciences, Faculty of Medicine & Health Sciences , Macquarie University , Sydney , New South Wales 2109 , Australia.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acs.biomac.9b00494
Publisher Site
http://dx.doi.org/10.1021/acs.biomac.9b00494DOI Listing
May 2019

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.

Cancer Chemother Pharmacol 2019 04 19;83(4):693-704. Epub 2019 Jan 19.

Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03780-yDOI Listing
April 2019

Monitoring Melanoma Using Circulating Free DNA.

Am J Clin Dermatol 2019 Feb;20(1):1-12

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0398-x
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0398-xDOI Listing
February 2019

Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.

Mamm Genome 2018 12 2;29(11-12):866-878. Epub 2018 Jul 2.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00335-018-9757-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267680PMC
December 2018

Evaluation of commercial kits for purification of circulating free DNA.

Cancer Genet 2018 12 29;228-229:21-27. Epub 2018 Aug 29.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia; The Poche Centre, Melanoma Institute Australia, NSW 2065, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22107762183025
Publisher Site
http://dx.doi.org/10.1016/j.cancergen.2018.08.005DOI Listing
December 2018

Oncogenic signaling in uveal melanoma.

Pigment Cell Melanoma Res 2018 11 23;31(6):661-672. Epub 2018 May 23.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12708DOI Listing
November 2018

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Oncogenesis 2018 Sep 20;7(9):72. Epub 2018 Sep 20.

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41389-018-0081-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148266PMC
September 2018

Interferon Signaling Is Frequently Downregulated in Melanoma.

Front Immunol 2018 21;9:1414. Epub 2018 Jun 21.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021492PMC
June 2018

Liquid biomarkers in melanoma: detection and discovery.

Mol Cancer 2018 01 17;17(1). Epub 2018 Jan 17.

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0757-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772714PMC
January 2018

The Role of Sumoylation in Senescence.

Adv Exp Med Biol 2017 ;963:215-226

Faculty of Medicine and Health Sciences, Macquarie University, NSW, Sydney, 2109, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-50044-7_13DOI Listing
September 2017

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

Clin Cancer Res 2017 Jun 3;23(12):2921-2923. Epub 2017 May 3.

Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0669DOI Listing
June 2017

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.

Cancer 2017 06;123(S11):2118-2129

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30435DOI Listing
June 2017

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Oncolytic Virother 2015 25;4:207-19. Epub 2015 Nov 25.

Centre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OV.S66086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918397PMC
August 2016

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Eur J Cancer 2016 07 24;62:76-85. Epub 2016 May 24.

Melanoma Institute Australia, 40 Rocklands Road, Wollstonecraft, NSW 2065, Australia; The University of Sydney, Sydney, NSW 2006, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.04.005DOI Listing
July 2016

Melanocyte reprogramming requires chromatin and transcription remodelling.

Pigment Cell Melanoma Res 2016 May 3;29(3):260-1. Epub 2016 Mar 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12457DOI Listing
May 2016

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

PLoS One 2015 6;10(4):e0123410. Epub 2015 Apr 6.

Melanoma Research, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123410PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386825PMC
April 2016

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Crit Rev Oncol Hematol 2015 Dec 28;96(3):385-98. Epub 2015 Aug 28.

Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.08.021DOI Listing
December 2015

The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.

Cell Signal 2015 Sep 3;27(9):1763-71. Epub 2015 Jun 3.

Centre for Cancer Research, The Westmead Millennium Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2015.05.011DOI Listing
September 2015

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Sci Signal 2015 Aug 18;8(390):ra82. Epub 2015 Aug 18.

Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria 3002, Australia. Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia. Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aab1111DOI Listing
August 2015

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

PLoS One 2014 14;9(4):e94748. Epub 2014 Apr 14.

Melanoma Institute of Australia, Sydney, New South Wales, Australia; The University of Sydney, Sydney, New South Wales, Australia; Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094748PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986217PMC
January 2015

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Clin Cancer Res 2015 Jan 4;21(1):98-105. Epub 2014 Nov 4.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia. Australian School of Advanced Medicine, Macquarie University, New South Wales, Australia. Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0759DOI Listing
January 2015

Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Oncoscience 2014 6;1(6):423-6. Epub 2014 Jun 6.

Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia ; Department of Medical Oncology, Westmead and Blacktown Hospitals, New South Wales, Australia ; Australian School of Advanced Medicine, Macquarie University, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284619PMC
http://dx.doi.org/10.18632/oncoscience.51DOI Listing
January 2015

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Cancer Res 2014 Dec 8;74(23):7037-47. Epub 2014 Oct 8.

Departments of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-1392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347853PMC
December 2014

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Nat Commun 2014 Dec 2;5:5694. Epub 2014 Dec 2.

1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6694DOI Listing
December 2014

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

J Invest Dermatol 2014 Nov 6;134(11):2795-2805. Epub 2014 Jun 6.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia; Melanoma Institute of Australia, North Sydney, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X153655
Publisher Site
http://dx.doi.org/10.1038/jid.2014.243DOI Listing
November 2014

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Pigment Cell Melanoma Res 2014 Nov 3;27(6):1126-37. Epub 2014 Jul 3.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12282DOI Listing
November 2014

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Mol Oncol 2014 May 15;8(3):544-54. Epub 2014 Jan 15.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528644PMC
May 2014

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Clin Cancer Res 2014 Apr 24;20(7):1965-77. Epub 2014 Jan 24.

Authors' Affiliations: Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute; Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia; Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney; Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3122DOI Listing
April 2014

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Cancer Discov 2014 Apr 27;4(4):423-33. Epub 2014 Jan 27.

1Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, 2Translational Research Laboratory, Cancer Therapeutics Program, 3Bioinformatics Core Facility, 4The Cancer Signalling Laboratory, Oncogenic Signaling and Growth Control Program, 5Gene Regulation Laboratory, Cancer Therapeutics Program, 6Molecular Imaging and Targeted Therapeutics Laboratory, Cancer Therapeutics Program, 7Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne; 8Sir Peter MacCallum Department of Oncology, Departments of 9Biochemistry and Molecular Biology, and 10Pathology, University of Melbourne, Parkville; 11Metabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University, Waurn Ponds; 12Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 13Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead; 14Department of Tissue Pathology & Diagnostic Oncology, Royal Prince Alfred Hospital; 15Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; 16Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; and 17Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110245PMC
April 2014

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

J Invest Dermatol 2014 Feb 6;134(2):488-497. Epub 2013 Aug 6.

School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2013.325DOI Listing
February 2014

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

Pigment Cell Melanoma Res 2013 Jul 13;26(4):518-26. Epub 2013 May 13.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12107
Publisher Site
http://dx.doi.org/10.1111/pcmr.12107DOI Listing
July 2013

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Mol Cancer Ther 2013 Jul 3;12(7):1332-42. Epub 2013 May 3.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0011DOI Listing
July 2013

Monitoring oncogenic B-RAF-induced senescence in melanocytes.

Methods Mol Biol 2013 ;965:313-26

Melanoma Institute Australia, North Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-239-1_21DOI Listing
June 2013

p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.

Pigment Cell Melanoma Res 2013 Mar 24;26(2):236-46. Epub 2013 Jan 24.

Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12062DOI Listing
March 2013

Human nevi lack distinguishing senescence traits.

Aging (Albany NY) 2013 Feb;5(2):98-9

Westmead Institute for Cancer Research and Melanoma Institute Australia, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616196PMC
http://dx.doi.org/10.18632/aging.100537DOI Listing
February 2013

Membrane and cytoplasmic marker exchange between malignant neoplastic cells and fibroblasts via intermittent contact: increased tumour cell diversity independent of genetic change.

J Pathol 2012 Dec 20;228(4):495-505. Epub 2012 Aug 20.

Cellular and Molecular Pathology Research Unit, Department of Oral Pathology and Oral Medicine, University of Sydney, Westmead Centre for Oral Health, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4063DOI Listing
December 2012

Absence of distinguishing senescence traits in human melanocytic nevi.

J Invest Dermatol 2012 Sep 19;132(9):2226-34. Epub 2012 Apr 19.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2012.126DOI Listing
September 2012

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

J Invest Dermatol 2012 Jul 22;132(7):1850-9. Epub 2012 Mar 22.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute and Melanoma Institute Australia, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2012.63DOI Listing
July 2012

Differential PAX3 functions in normal skin melanocytes and melanoma cells.

Biochem Biophys Res Commun 2011 Aug 23;411(4):832-7. Epub 2011 Jul 23.

School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, WA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2011.07.053DOI Listing
August 2011

Oncogene-induced senescence pathways in melanocytes.

Cell Cycle 2010 Dec 15;9(24):4778-9. Epub 2010 Dec 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.24.14248DOI Listing
December 2010

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

Hum Mutat 2010 Jun;31(6):692-701

Westmead Institute for Cancer Research and Melanoma Institute of Australia, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.21245DOI Listing
June 2010

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Cell 2010 May;141(4):717-27

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
https://www.systembio.com/downloads/Scurr_2010.pdf
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S009286741000438
Publisher Site
http://dx.doi.org/10.1016/j.cell.2010.04.021DOI Listing
May 2010

Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria.

Cell Cycle 2010 Feb 2;9(4):829-39. Epub 2010 Mar 2.

Westmead Institute for Cancer Research and Melanoma Institute of Australia, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.4.10785DOI Listing
February 2010

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

J Invest Dermatol 2009 Aug 12;129(8):1983-91. Epub 2009 Feb 12.

Westmead Institute for Cancer Research, Westmead Hospital, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2009.5DOI Listing
August 2009

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Aging (Albany NY) 2009 May 16;1(6):542-56. Epub 2009 May 16.

Westmead Institute for Cancer Research and Melanoma Institute of Australia, University of Sydney at Westmead, Westmead NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806033PMC
http://dx.doi.org/10.18632/aging.100051DOI Listing
May 2009

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.

Mol Cancer 2009 Jan 16;8. Epub 2009 Jan 16.

Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute and Westmead Hospital, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-8-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644676PMC
January 2009

p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Neoplasia 2008 Nov;10(11):1231-9

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570599PMC
http://dx.doi.org/10.1593/neo.08702DOI Listing
November 2008

Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.

Clin Cancer Res 2008 Nov;14(21):6924-32

Westmead Institute for Cancer Research, University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-5189DOI Listing
November 2008

p16INK4a-induced senescence is disabled by melanoma-associated mutations.

Aging Cell 2008 10;7(5):733-45

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582406PMC
http://dx.doi.org/10.1111/j.1474-9726.2008.00422.xDOI Listing
October 2008

Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF.

Int J Cancer 2007 Aug;121(4):784-90

Oncogenomics Laboratory, Queensland Institute of Medical Research, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22725DOI Listing
August 2007

p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.

Cell Cycle 2007 Jul 10;6(14):1741-7. Epub 2007 May 10.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.6.14.4428DOI Listing
July 2007

Physical and functional interaction of the p14ARF tumor suppressor with ribosomes.

J Biol Chem 2006 Dec 11;281(49):38080-8. Epub 2006 Oct 11.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M609405200DOI Listing
December 2006

The ARF tumour suppressor.

Int J Biochem Cell Biol 2006 28;38(10):1637-41. Epub 2006 Feb 28.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2006.02.008DOI Listing
October 2006

The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired.

Int J Cancer 2005 Nov;117(4):569-73

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.21265DOI Listing
November 2005

p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners.

Cell Cycle 2005 Apr 7;4(4):597-603. Epub 2005 Apr 7.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.4.4.1597DOI Listing
April 2005

Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis.

Cell Cycle 2005 Mar 7;4(3):465-72. Epub 2005 Mar 7.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.4.3.1526DOI Listing
March 2005

Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition.

J Biol Chem 2003 Feb 21;278(7):4981-9. Epub 2002 Nov 21.

Westmead Institute for Cancer Research, University of Sydney, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M210978200DOI Listing
February 2003